Laura M. Venier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura M. Venier has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Dimpy Modi
Faculty of Health Sciences, Medical Sciences Graduate Program McMaster University Hamilton Ontario Canada
3 shared publications - Adam Cuker
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
2 shared publications Daya Gill
Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada
2 shared publications- Donald M. Arnold
Department of Medicine, McMaster University, Hamilton, Canada
2 shared publications Emily Xu
Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada
2 shared publicationsIshaq Siddiqui
Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada
2 shared publications
Latest Publications
- Open Access
- 8 July 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (13) , 3238-3248
Critical bleeding in adults and children with immune thrombocytopenia: a multicenter cohort study
Critical bleeding in patients with immune thrombocytopenia (ITP) is a life-threatening hematologic emergency. This study aimed to describe the frequency, management, and outcomes of critical bleeds among adults and children with ITP. We conducted a retrospective cohort study of patients with ITP who presented to the emergency room with a platelet count <20 × 109/L across 7 centers in the United States and Canada between 2010 and 2019. Of 1226 patients (n = 296 adults; n = 930 children), 28 (2.3%) had critical bleeds (adults, n = 15 [median age, 68 years]; children, n = 13 [median age, 11 years]). Of patients with critical bleeds, 12 adults (80.0%) and 6 children (46.2%) had intracranial hemorrhage (ICH). For adults, the common interventions used to treat critical bleeds were platelet transfusions (n = 11 [73.3%]), corticosteroids (n = 10 [66.7%]), and IV immunoglobulin (n = 8 [53.3%]), and for children, common interventions were IV immunoglobulin (n = 10 [76.9%]), corticosteroids (n = 8 [61.5%]), platelet transfusions (n = 8 [61.5%]), thrombopoietin receptor agonists (n = 4 [30.8%]), and antifibrinolytic agents (n = 4 [30.8%]). For both adults and children, the most common treatment combination was corticosteroids, IV immunoglobulin, and platelet transfusion (n = 6 [40.0%] vs n = 6 [46.2%]). The median time from presentation to first treatment was 6.9 hours for adults and 3.5 hours for children. Overall, 9 patients (32.1%) with critical ITP bleeds died, including 7 adults (46.7%) and 2 children (15.4%). Critical bleeding in patients with ITP was rare but frequently fatal, especially among older adults with ICH and when treatments were delayed.
- 8 July 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (13) , 3238-3248
Open AccessCritical bleeding in adults and children with immune thrombocytopenia: a multicenter cohort study
Critical bleeding in patients with immune thrombocytopenia (ITP) is a life-threatening hematologic emergency. This study aimed to describe the frequency, management, and outcomes of critical bleeds among adults and children with ITP. We conducted a retrospective cohort study of patients with ITP who presented to the emergency room with a platelet count <20 × 109/L across 7 centers in the United States and Canada between 2010 and 2019. Of 1226 patients (n = 296 adults; n = 930 children), 28 (2.3%) had critical bleeds (adults, n = 15 [median age, 68 years]; children, n = 13 [median age, 11 years]). Of patients with critical bleeds, 12 adults (80.0%) and 6 children (46.2%) had intracranial hemorrhage (ICH). For adults, the common interventions used to treat critical bleeds were platelet transfusions (n = 11 [73.3%]), corticosteroids (n = 10 [66.7%]), and IV immunoglobulin (n = 8 [53.3%]), and for children, common interventions were IV immunoglobulin (n = 10 [76.9%]), corticosteroids (n = 8 [61.5%]), platelet transfusions (n = 8 [61.5%]), thrombopoietin receptor agonists (n = 4 [30.8%]), and antifibrinolytic agents (n = 4 [30.8%]). For both adults and children, the most common treatment combination was corticosteroids, IV immunoglobulin, and platelet transfusion (n = 6 [40.0%] vs n = 6 [46.2%]). The median time from presentation to first treatment was 6.9 hours for adults and 3.5 hours for children. Overall, 9 patients (32.1%) with critical ITP bleeds died, including 7 adults (46.7%) and 2 children (15.4%). Critical bleeding in patients with ITP was rare but frequently fatal, especially among older adults with ICH and when treatments were delayed.
- Open Access
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 7239
Treatment of Critical Bleeding Events in Patients with Immune Thrombocytopenia: A Systematic Review
Disclosures. Cuker:New York Blood Center: Consultancy; Synergy: Consultancy; UpToDate: Patents & Royalties; MingSight: Consultancy. Kang:Amgen: Consultancy,
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 7239
Open AccessTreatment of Critical Bleeding Events in Patients with Immune Thrombocytopenia: A Systematic Review
Disclosures. Cuker:New York Blood Center: Consultancy; Synergy: Consultancy; UpToDate: Patents & Royalties; MingSight: Consultancy. Kang:Amgen: Consultancy,
- 27 December 2022
- Published by Springer Nature in International Journal of Hematology
- Vol. 117 (3) , 341-348
Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a highly prothrombotic disorder caused by anti-PF4 antibodies that activate platelets and neutrophils, leading to thrombosis. Heparin-induced thrombocytopenia (HIT) is a related anti-PF4 mediated disorder, with similar pathophysiology and clinical manifestations but different triggers (i.e., heparin vs adenoviral vector vaccine). Clinically, both HIT and VITT typically present with thrombocytopenia and thrombosis, although the risk of thrombosis is significantly higher in VITT, and the thromboses occur in unusual anatomical sites (e.g., cerebral venous sinus thrombosis and hepatic vein thrombosis). The diagnostic accuracy of available laboratory testing differs between HIT and VITT; for VITT, ELISAs have better specificity compared to HIT and platelet activation assays require the addition of PF4. Treatment of VITT and HIT is anticoagulation non-heparin anticoagulants; however, heparin may be considered for VITT if no other option is available.
- 27 December 2022
- Published by Springer Nature in International Journal of Hematology
- Vol. 117 (3) , 341-348
Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a highly prothrombotic disorder caused by anti-PF4 antibodies that activate platelets and neutrophils, leading to thrombosis. Heparin-induced thrombocytopenia (HIT) is a related anti-PF4 mediated disorder, with similar pathophysiology and clinical manifestations but different triggers (i.e., heparin vs adenoviral vector vaccine). Clinically, both HIT and VITT typically present with thrombocytopenia and thrombosis, although the risk of thrombosis is significantly higher in VITT, and the thromboses occur in unusual anatomical sites (e.g., cerebral venous sinus thrombosis and hepatic vein thrombosis). The diagnostic accuracy of available laboratory testing differs between HIT and VITT; for VITT, ELISAs have better specificity compared to HIT and platelet activation assays require the addition of PF4. Treatment of VITT and HIT is anticoagulation non-heparin anticoagulants; however, heparin may be considered for VITT if no other option is available.
- 17 March 2022
- Published by Wiley in American Journal of Hematology
- Vol. 97 (5) , 659-665
Acute thrombocytopenia suggesting thrombotic microangiopathy
- 17 March 2022
- Published by Wiley in American Journal of Hematology
- Vol. 97 (5) , 659-665
Acute thrombocytopenia suggesting thrombotic microangiopathy